novartis ag-adr (NOTA:Frankfurt)
Transactions by NOVARTIS AG-ADR (NOTA) in the last 6 months
Elanco Animal Health, Inc entered into an agreement to acquire the assets of Novartis Animal Health Inc. from Novartis AG (SWX:NOVN) for approximately $5.4 billion in cash on April 22, 2014. The consideration is subject to working capital and other adjustments. Eli Lilly, the parent company of Elanco Animal Health plans to fund this acquisition with approximately $3.4 billion of cash-on-hand and $2 billion in debt to be issued. Novartis Animal Health Inc. reported revenues ...
Novartis AG (SWX:NOVN) entered into an agreement to acquire marketed oncology portfolio, related R&D activities and AKT inhibitor from GlaxoSmithKline plc (LSE:GSK) for $16 billion in cash on April 22, 2014. The consideration amount is subject to customary adjustment for levels of working capital. Up to $1.5 billion of the amount depends on the results of the COMBI-d trial. In the event of termination of transaction, GlaxoSmithKline has agreed to pay Novartis a termination ...
GlaxoSmithKline plc (LSE:GSK) entered into a share and business sale agreement to acquire global Vaccines business from Novartis AG (SWX:NOVN) for $7.1 billion on April 22, 2014. Under the terms of the agreement, Glaxo agreed to pay $5.25 billion at closing with subsequent potential milestone payments and ongoing royalties, including $450 million upon FDA regulatory approval for Novartis' MenABCWY vaccine product, $450 million in the event that Bexsero achieves an agreed ...
Novartis AG (SWX:NOVN) acquired CoStim Pharmaceuticals Inc. from Atlas Venture L.P. Partners, Innovation Fund, MPM Capital and others on February 17, 2014.
Partners Innovation Fund
|3M Co||$144.31 USD||+0.42|
|Bayer AG||€101.21 EUR||0.00|
|Gilead Sciences Inc||$88.73 USD||-0.21|
|Novo Nordisk A/S||kr247.80 DKK||0.00|
|Procter & Gamble Co/The||$81.16 USD||-0.45|
|View Industry Companies|